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Abbreviation Text 
 
   ADR Adverse drug reaction 
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ICPC The International Classification of Primary Care 
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NGAPC National guidelines for use of antibiotics in primary care  
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 PDR Pan-drug resistant  
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RTI Respiratory tract infections  
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UTI Urinary tract infections  
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4 Summary 
Background. Two undeniable challenges facing modern medicine are the increasing problems of 
antimicrobial resistance and the lack of new antibiotics to combat infections. Alone these problems are 
serious, but the synergy of these two problems threatens to return us to the pre-antibiotic era. These 
problems are global and affect all levels of the health care system, from the rural family physician to the 
intensive care unit of tertiary hospitals. Rational antibiotic prescribing is paramount in meeting the 
challenges of antibacterial resistance. In Norway, approximately 90 % of all antibiotics are prescribed in 
primary care. The aim of this thesis is to elucidate antibiotic prescribing in selected primary care settings 
to identify possible areas for improvement. 
Methods. Papers I and II are retrospective examinations of patient records at nursing homes over a one 
year period to identify the infection being treated with antibiotics and whether the choice of antibiotic was 
in line with the national guidelines for antibiotic treatment. In paper I the extent of microbiologic 
diagnostics ordered prior to empiric antibiotic therapy is registered. 
Paper III examines positive urine cultures from patients 65 years and older living in 34 different nursing 
homes over a thirteen month period and compared etiology and resistance rates of uropathogens isolated 
from patients 65 years and older living at home. 
Paper IV is a non-randomized controlled cluster intervention study comparing antibiotic prescribing for 
cystitis and pyelonephritis prior to and after an intervention  
 
Results. Paper I. 94 infections were treated with ciprofloxacin. Urinary tract infection (UTI) was the most 
common infection both on the long-term (78 %) and the short-term wards (40 %). Respiratory tract 
infection was almost as common as UVI on short-term wards (37 %), but was uncommon on long-term 
wards (4 %). Specific bacterial etiology was identified in 44 infections (47 %), 12 of these by bacteria 
only susceptible for ciprofloxacin. 
Paper II. 714 antibiotic courses were prescribed to 327 patients yielding a prevalence of patients treated 
with antibiotics of 6.6 %. Prescribing compliant with national guidelines was 77 % for UTI, 79 % for 
RTI, and 76 % for skin and soft tissue infections (SSTI). Ciprofloxacin was responsible for 63 % of non-
compliant prescribing. On the short-term wards there was a higher rate of total prescribing, non-compliant 
prescribing, and prescribing by physicians employed at the local hospital 
Paper III. In both the nursing home group and in the group living at home Escherichia coli (64 % both 
groups) was the most commonly cultured bacteria followed by Enterococcus faecalis (10 % vs 8 % 
respectively). Escherichia coli was also the most commonly cultured bacteria in females (70 %) and 
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males (39 %), but Enterococcus faecalis was significantly more common in males (18 %) than females (7 
%) (p < 0.05). For males there was a significantly higher resistance rates to ciprofloxacin for Escherichia 
coli than for females (12 % vs 7 %; p < 0.05) and to mecillinam for Proteus mirabilis (12 % vs 3 %; p < 
0.05).  
Paper IV. In the targeted emergency department (ED), there was a significant (p < 0.05) reduction in 
ciprofloxacin prescribing and a significant increase in mecillinam prescribing for cystitis (p = 0.042). In 
the control ED, prescribing of ciprofloxacin doubled (p < 0.05). There were no significant changes in 
antibiotic prescribing for pyelonephritis in either ED. 
 
Conclusion. The areas of improvement identified in this thesis include pre therapy microbiologic 
diagnostics, the need to consider restrictions on prescribing broad spectrum antibiotics, and the need for 
specific guidelines for the elderly based on gender for the treatment of UTI.  
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5 Sammenfatning på norsk 
Bakgrunn. To store utfordringer moderne infeksjonsmedisin må forholde seg til er økende 
antibiotikaresistens og mangel på nye antibiotika. Hver for seg er disse utfordringer alvorlige, sammen 
truer de med å sende oss tilbake til tiden før antibiotika. Disse utfordringer er globale og påvirker alle 
nivåer i helsevesenet, fra fastleger, til sykehjem, til intensivavdelinger ved sykehus. Rasjonell 
antibiotikaforskrivning er avgjørende i kampen mot utvikling av resistens. I Norge blir omtrent 90 % av 
alle antibiotika foreskrevet i primærhelsetjenesten. Målet med denne oppgaven er å belyse 
antibiotikaforskrivning i deler av primærhelsetjenesten og identifisere mulige områder for forbedring. 
Metode. Artikkel I og II er retrospektive undersøkelser av pasientjournaler ved sykehjem over en ett-års 
periode for å identifisere alle infeksjoner behandlet med antibiotika, og om valg av antibiotika var i tråd 
med de nasjonale retningslinjer for antibiotikabehandling. I artikkel I registrerte vi omfang og resultat av 
mikrobiologisk diagnostikk forut for antibiotikabehandling. I artikkel II undersøkte vi etterlevelsen 
(compliance) med de nasjonale retningslinjene for antibiotikaforskrivning i allmennpraksis 
Artikkel III undersøkte positive urindyrkningssvar fra pasienter 65 år og eldre som bodde i 34 forskjellige 
sykehjem sammenlignet med dyrkningssvar fra pasienter 65 år og eldre som bodde hjemme i samme 
tidsperiode. 
Artikkel IV var en ikke-randomisert kontrollert klynge-intervensjonstudie som sammenlignet 
antibiotikaforskrivning mot cystitt og pyelonefritt før og etter en intervensjon. 
Resultater. Artikkel I. 94 ciprofloksacinkurer ble forskrevet til 78 pasienter ved sykehjem. Ingen 
pasienter fikk ofloksacin. Urinveisinfeksjon var den hyppigste indikasjon for pasienter på både langtids 
(78 %) og korttidsavdelinger (40 %). Luftveisinfeksjon var en nesten like hyppig indikasjon på 
kortidsavdelinger (37 %), men var det sjelden på langtidsavdelingene (4 %). 44 infeksjoner (47 %) ble 
verifisert med mikrobiologisk undersøkelse. 12 infeksjoner var forårsaket av en mikrobe som kun var 
følsom for ciprofloksacin. 
Artikkel II. 714 antibiotikakurer ble foreskrevet til 327 pasienter ved sykehjem som ga en prevalens på 
6,6 %. Forskrivningen var i tråd med antibiotika retningslinjer i 77 % av tilfellene for UVI, 79 % for LVI, 
og 76 % for hud- og bløtdelsinfeksjoner. Ciprofloxacin ble forskrevet i 63 % av forskrivninger som ikke 
var i tråd med retningslinjene. På korttidsavdelinger var det en høyere andel av forskrivning som ikke var 
i tråd med retningslinjer, og forskrivningen av de kurene var initiert av leger ansatt ved det lokale 
sykehuset. 
  
12 
 
 
Artikkel III. Hos både sykehjemspasienter og hjemmeboende pasienter var Escherichia coli (64 % begge 
gruppene) den vanligste bakterien fulgt av Enterococcus faecalis (10 % vs 8 %). Escherichia coli var 
også den vanligste bakterien dyrket hos kvinner (70 %) og menn (39 %), men Enterococcus faecalis var 
betydelig mer vanlig hos menn (18 %) enn hos kvinner (7 %) (p <0,05). Hos menn var en signifikant 
høyere andel Escherichia coli resistent mot ciprofloksacin enn hos kvinner (12 % vs 7 %, p <0,05), og 
høyere andel Proteus mirabilis resistent mot mecillinam (12 % vs 3 %, p <0,05). 
Artikkel IV. Ved intervensjonslegevakten var det en signifikant reduksjon i ciprofloksacinforskrivning (p 
< 0,05), og en signifikant økning i mecillinamforskrivning  for cystitt (p = 0.042). I kontroll-legevakten 
var det en signifikant økning i ciprofloksacinforskrivning i den samme perioden (p < 0,05). Det var ingen 
signifikante endringer i antibiotikaforskrivning  for pyelonefritt ved begge legevakter.  
 
Konklusjon. Områdene med forbedringspotensiale identifisert i denne avhandlingen inkluderer økt 
mikrobiologisk diagnostikk forut for behandling, behov for å vurdere restriksjoner på forskrivning av 
bredspektrede antibiotika, og behov for spesifikke retningslinjer for behandling av UVI hos eldre, basert 
på kjønn.  
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6 Introduction 
Antibiotic: tending to prevent, inhibit, or destroy life 
1(Webster’s Dictionary) 
 
In 2005, I started working at a nursing home in Arendal with both long-term patients and patients 
admitted for short-term rehabilitation. In the first weeks of work three patients transferred from the 
local hospital to my ward were being treated with ciprofloxacin. I called the microbiology 
laboratory for resistance results with the intention of changing to a narrower spectrum antibiotic if 
results allowed for this. There were, however, no culture results. I was left no option but to continue 
the ciprofloxacin treatment. Over the next year this situation reoccurred several times. I began to 
wonder about the extent of this problem, if it was indeed a problem. With this wondering the 
systematic evaluation which led to the first article about fluoroquinolone use in the nursing home 
was in swing, and the process culminating in this thesis began.  
6.1 Historical Background 
“Those who cannot remember the past are condemned to repeat it.” George Satayana. The Life of 
Reason. 1905.  
 
Evidence exists that both the ancient Chinese 
2
 and indigenous people of South America 
3
 knew of 
the antimicrobial effects of plant extracts. In the 1600‘s western Europeans benefited from this 
knowledge documented by the use of the quinine-containing bark of the cinchona tree for the 
symptomatic treatment of malaria.  
By the late 1800‘s scientists were aware of substances demonstrating intermicrobic 
antagonism. In vitro observations gave hope that these substances could be used therapeutically, but 
serious toxicity limited their use 
4
. There was a need for development of agents toxic to microbes 
yet safe for human cells. This quest for the ―magic bullet‖ by Paul Ehrlich (1854 – 1915) led to the 
development of Salvarsan a synthetic arsenic-containing drug used successfully in the treatment of 
syphilis. Unfortunately, toxicity was again unacceptably high.  
The term ―antibiotic‖ was first used by Selman Waksman (1888-1973) in 1942 5,6. He 
defined antibiotics as chemotherapeutic agents produced by microorganisms to inhibit growth of 
other microorganisms. Although not an antibiotic by this definition, the synthetically produced 
sulfonamides preceded penicillin as the first therapeutically effective and relatively non-toxic 
antimicrobial agents. Alexander Fleming (1881-1955) discovered penicillin serendipitously in 1929 
7
 but it was not until the late 1930‘s that Howard Florey (1898-1968) demonstrated penicillin‘s 
curative effects in mice 
8. In 1941 the first report of penicillin‘s curative effect in humans was 
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published 
9. By the mid 1940‘s and for perhaps the first time in the history of man, the enormous 
rate of morbidity and mortality bacterial infections caused seemed to be overcome. 
  
6.2 After penicillin: The golden age  
‗One can think of the middle of the twentieth century as the end of one of the most important social 
revolutions in history, the virtual elimination of the infectious diseases’  
Frank MacFarlane Burnet, Natural history of infectious disease.1962 
10
 
 
From the early 1940‘s until the early 1960‘s over half of the antibiotics now in use were developed 
giving rise to antibiotic‘s ―Golden Age» (figure 1) 11. The pharmaceutical industry began playing a 
more important role in the discovery and development of new antibiotics. The same techniques of 
first screening biological material for evidence of antibacterial actions and thereafter isolating and 
purifying the agent for clinical use were utilized. In 1944 the first aminoglycoside and effective 
anti-tuberculosis drug, streptomycin, was developed. Soon thereafter this, the discovery of 
chloramphenicol, the first broad spectrum antibiotic, occurred. In the span of the next 15 years 
several new classes of antibacterial drugs were developed including the cephalosporins, 
tetracyclines, marcrolides, glycopeptides, and lincosamides. In addition to these drugs the semi-
synthetic agent methicillin and the synthetic agents nitrofurantoin, isoniazid, metronidazole, 
trimethoprim and the quinolones were discovered in this time period.  
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Figure 1. Antibiotic development 1900-2010. The tan boxes are synthetic antibiotics while the 
green boxes are antibiotics discovered by screening natural products.  Methicillin (not shown in the 
figure) was developed in 1959 (reproduced with permission) 
12
 
 
6.3 Newer developments: “The innovation gap” or development void 
From the early 1960‘s the development of new antibacterial agents has slowed significantly and no 
new classes of antibiotics have been discovered since 1987 
13
. There are several factors contributing 
to this hiatus. One of these is the limits of selective screening. After almost 20 years, it seems that 
the possibility of discovering new antibiotics by this technique is exhausted. The shift to techniques 
using genomics 
14
 developing new agents targeting known microbial structures like the bacterial 
cell wall, tRNA synthesis, transcription, and DNA-replication have not yet been as fruitful. 
Modifications in existing antimicrobial agents have resulted in new generations of agents within 
these classes. Unfortunately, these modest developments are dwarfed by the rapidly expanding 
problem of bacterial resistance to antibiotics. 
Scientific challenges are not alone in explaining the development void and science alone 
cannot remedy the problem. Both the economics of the pharmaceutical industry and regulation 
barriers have a significant role contributing to the hiatus 
15
. Antibiotics are used for short periods of 
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time, and should be prescribed restrictively. Medications for chronic conditions like diabetes or 
hypertension are prescribed commonly and over long time periods. In terms of economic return for 
investment in development, it is clear that antibiotics cannot compete with medications for chronic 
illness 
13
. Hinders to development due to regulations also contribute to the problem 
15,16
. There are 
several areas of improvement. One example is setting reasonable requirements for non-inferiority 
for new antibiotics. Another regulatory issue is improving patent laws to ensure costly investments 
in antibiotic development are compensated by extending patents. Without addressing these issues to 
stimulate development the resulting lack of new agents coupled with increasing resistance problems 
will result in a return to the pre antibiotic era 
17,18
.  
Novel approaches are necessary to solve the problem. Researchers need to think differently 
to discover new antimicrobial medications. Funding sources, both private and public, must 
coordinate efforts in order to share resources necessary for new development 
19
. Finally, 
unnecessarily strict regulatory obstacles hindering use in patients must be modified 
15
.  
 
6.4 Antibacterial Resistance 
―Although resistance is inevitable, the pace and extent of propagation of resistant organisms is 
governed by human behavior” Kieran Hand. Antibiotic Stewardship, 2013 20 
 
In his acceptance speech at the Nobel Prize ceremony in 1945 Fleming warned of the problem of 
resistance to penicillin 
21
. There are an enormous number (10
15
) of bacteria in and on the human 
body. The replication time for many bacteria is less than one hour. Combining these two facts with 
the selection pressure antibiotics exert on bacteria make resistance development inevitable.  
Antibiotic resistance is an all-encompassing term for a heterogeneous group of 
mechanisms. These mechanisms are defined by the action of the particular antibiotic and are 
intimately linked to the biology of the target microbe (figure 2). One can roughly divide antibiotics 
into those targeting the bacterial cell wall and those targeting cytoplasmic structures responsible for 
protein synthesis or cell replication. For example, β-lactam antibiotics like penicillin act on the cell 
wall. Bacteria have developed genes which are responsible for β-lactamases. These enzymes cleave 
the beta-lactam ring of the antibiotic rendering the antibiotic inactive. Another example is 
tetracycline which acts on the intracellular 30S portion of RNA inhibiting bacterial protein 
synthesis. Bacteria combat tetracycline by developing efflux pumps flushing tetracycline out of the 
bacteria before it can act on the bacterial RNA.  
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Figure 2. Target locations of antibacterial drugs. Arrows pointing into the cytoplasm indicates 
intracellular target while arrows pointing to the cell wall indicate extracellular target (reproduced 
with permission)
12
  
 
There are pharmacologic strategies to combat these resistance mechanisms. Β-lactamases 
can be counteracted with the antagonist clavulanic acid. Here, scientists have found a weapon to 
destroy the bacteria‘s ―anti-antibiotic‖ weapon. A more common strategy to combat resistance 
development is to modify the core structure common in a specific antibiotic class 
13
. This produces 
a new generation antibiotic with characteristics against which bacteria have not yet developed 
resistance. Examples of new generation antibiotics are found in the penicillin, cephalosporin, 
quinolone, macrolides and tetracycline classes. This has been responsible for the majority of ―new― 
antibiotics developed after 1960.  
Unfortunately bacterial biology has circumvented these pharmacological strategies giving 
rise to multi-drug resistant (MDR) and pan-drug resistant organisms (PDR). Transmission of 
resistance occurs vertically and horizontally. Vertical transmission occurs when a bacteria has 
developed resistance and passes on the genes responsible for the resistance phenotype to its 
progeny. Horizontal transmission, which is generally facilitated by extra-chromosomal genetic 
elements (plasmids), enables bacteria to ―infect‖ other bacteria with resistance genes. Often these 
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extra-chromosomal genetic elements code for several different forms of resistance and have been 
the culprits responsible for extended β-lactamase resistance (ESBL) and MDR/PDR.  
There is a clear association between resistance prevalence and the use of antibiotics. 
European countries with the highest rates of outpatient use of penicillin (ATC code J01) had the 
highest rates of penicillin non-susceptible Streptococcus pneumonia (S pneumonia) (figure 3) 
22
. 
Another study suggested that the observed higher rate of resistant S pneumonia in Atlanta was 
associated with a higher use of antibiotics in the same population 
23
. Comparing data on total 
antibiotic prescription rates with antibiotic resistance rates for both E coli and Klebsiella 
pneumoniae (K pneumoniae) reveal a clear association; the countries with the highest prescription 
rates have the highest resistance rates  
22,24
.  
 
Figure 3. Correlation between outpatient use of penicillins and penicillin resistance in 
Streptococcus pneumoniae in Europe. (Reproduced with permission (Copyright © 2005 Elsevier 
Ltd. Goossens H, et al. The Lancet 2005 365, 579-587DO)
22
 
 
The same correlation is seen on the individual patient level. Patients treated with antibiotics for 
respiratory tract (RTI) or urinary tract infections (UTI) have a higher rate of resistant microbes in 
their respiratory and urinary tracts after treatment 
25,26
. Antibiotic use alters the normal flora of the 
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patient‘s skin, oropharynx, vagina and gut. This microflora has a protective function for the 
individual patient and serves as a potential barrier for colonization of pathologic opportunistic MDR 
bacteria 
27
. This is especially true for the gut flora. Once colonized, these patients serve as a 
reservoir for spread of MDR bacteria. 
 
6.5 The situation in Norway 
6.5.1 Antibiotics in Norway 
Approximately 90 % of antibiotics are prescribed by primary care physicians in Norway 
28
. Both the 
rate of prescribing and the relative predominance of narrow spectrum antibiotic prescribing is 
favorable in comparison to most other European countries 
29
. Despite this relatively admirable 
situation, antibiotic prescribing has increased 56 % from 12.6 to 19.6 defined daily dose 
(DDD)/1000 inhabitants/day since 1974 
30
 (figure 4). There has been a slight increase in the 
percentage of broad spectrum antibiotic prescribing but phenoxymethyl penicillin (Anatomic 
therapeutic code (ATC) J01CE02) is still the most commonly prescribed antibiotic 
28,30,31
. Young 
children and the elderly over the age of 75 have the highest prevalence of antibiotic use and females 
use more antibiotics than men for all age groups 
30
.  
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Figure 4. Antibiotic sales in Norway from 1974 by ATC group. (Reproduced with permission)
30
 
 
6.5.2 Resistance in Norway 
Along with the other Scandinavian countries, antibiotic resistance problems have been moderate in 
Norway compared to other European countries 
24
. This is not to say that resistance problems are 
non-existent. Finland has had a problem with macrolide-resistant group A streptococci 
32
 and 
Iceland has had a serious problem with penicillin-resistant streptococci 
33
. In Norway, the 
prevalence of ESBL producing E coli and K pneumoniae has increased and methicillin-resistant 
Staphylococcus aureus (MRSA) is also a problem. There is an association between antibiotic 
prescribing and resistance development clearly illustrated by E coli resistance to ciprofloxacin 
(figure 5) 
34
. Whether resistance problems are a direct result of this practice is a subject of debate 
35
. 
Central in the debate is whether the increase in resistant bacteria is due to selection pressure created 
by high use of antibiotics, or whether the resistance is due to imported clones which circulate in the 
environment periodically. Regardless of this debate, the need for prudent antibiotic prescribing is 
obvious. 
 
 
Figure 5. Ciprofloxacin usage (blue) and E coli non-susceptibility (red) (reproduced with 
permission, NORM/NORM-VET 2013. Usage of Antimicrobial Agents and Occurrence of 
Antimicrobial Resistance in Norway) 
34
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6.6 More about ciprofloxacin 
Ciprofloxacin (ATC J01MA02) is the broadest spectrum antibiotic available in Norway for per os 
administration. It is a member of the quinolone family of antibiotics, a second generation quinolone 
derived from nalidixic acid. These agents bind to bacterial DNA topoisomerase and DNA gyrase 
enzymes disrupting DNA replication and transcription leading to bacterial cell death. Before 
problems with resistance, ciprofloxacin was especially effective against gram negative organisms of 
the Enterobacteriacea family (e.g. E coli, K pneumoniae, P mirabilis) making it a popular choice for 
treating UTI.  
Although its mechanism of action enables ciprofloxacin to be effective against gram 
positive organisms, its relatively high minimum inhibitory concentration (MIC-90) value (2-4 
µg/ml) 
36
 makes it unsuitable for treating infections where aerobic gram positive organisms like S 
pyogenes and S pneumonia cause disease. This is supported by therapy failures in clinically 
important bacterial infections such as pneumonia and acute otitis media (AOM) 
37,38
.  
Ciprofloxacin and ofloxacin were the first second-generation fluoroquinolones marketed in 
Norway. Initially and up until 2008, ciprofloxacin was only approved for empiric treatment of 
complicated UTI, serious Salmonella infections, and osteomyelitis 
39
. Although ciprofloxacin has 
received approval for marketing its use in a wider range of infections 
40
, the national guidelines for 
use of antibiotics in primary care (NGAPC) 
41
 do not recommend ciprofloxacin as first choice 
empiric treatment for any infection. 
Fluoroquinolone prescribing, primarily ciprofloxacin, has increased 74 % in the last decade 
from 0.43 DDD/1000 inhabitants in 2002 to 0.75 DDD/1000 inhabitants in 2012 
28
. In Norway, E 
coli resistance to ciprofloxacin has paralleled this trend increasing from 2.2 % in 2002 to 11.3 in 
2012 (figure 5) 
28
 . Internationally, ciprofloxacin has been associated with other serious forms of 
resistance including ESBL 
42
 especially in the elderly. In addition to these resistance problems, 
ciprofloxacin has been linked to Clostridium difficile (C difficile) infections 
43
.  
 
Ciprofloxacin can be administered both orally and intravenously. It is absorbed rapidly and 
has relatively good penetration in all tissues. Excretion occurs via both renal and hepatic pathways. 
From 10-30 % of orally administered drug appears in the gut. Approximately 40-50 % appears in 
the urine as unchanged drug.  Ciprofloxacin is also excreted in sweat and contributes to resistance 
development in normal skin bacterial flora 
44.
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In younger adults there are relatively few side effects. In the elderly, however, both side 
effects and interactions are more common 
45
 
46
. Central nervous side effects are the most commonly 
reported side effects after gastrointestinal side effects making its use in the nursing home potentially 
problematic. Like several other antibiotics, ciprofloxacin can result in prolonged prothrombin time 
in patients using warfarin. 
 
6.7 Untoward effects 
―Collateral damage: injury inflicted on something other than an intended target” Webster’s 
Dictionary
1
 
Ecologic effects 
The disadvantages of antibiotics are not limited to resistance problems. As mentioned 
previously, antibiotic use can have detrimental effects on patients‘ natural flora. The vacant 
ecological niche created by the disappearance of a patient‘s natural flora by antibiotics can be 
occupied by pathological opportunistic microbes. A serious example of this is antibiotic-induced 
pseudomembranous colitis caused by Clostridium difficile. This form of diarrhea is the most 
common heath care acquired infection in the USA, the most common cause of hospital-acquired 
diarrhea and the most common cause of gastroenteritis-associated death 
47,48
. Other less serious 
examples of opportunistic infections occurring in the wake of antibiotic treatment are other forms of 
antibiotic associated diarrhea and Candida vaginitis.  
Adverse reactions 
Adverse drug reactions (ADR) to antibiotics range from life threatening conditions such as 
anaphylaxis, hepatic failure, bone marrow suppression and Steven‘s Johnson‘s syndrome to less 
serious but bothersome side effects like nausea and skin rashes. It is difficult to estimate the exact 
incidence of side effects of antibiotics in Norway. Registration of side effects is based on 
spontaneous reporting and therefore significantly underestimates the actual incidence. This is 
especially true for non-serious side effects as patients do not always seek medical care for these 
symptoms. Even when they do, there is a small and variable chance that the physician will report 
these side effects.  
Studies from abroad indicate that side effects such as diarrhea 
49
 occur in 5-25 % and rash 
50
 in 2-4 % of patients. Though often self-limiting and uncomfortable, ADR are responsible for 
physician consultations, work absence and in some cases serious morbidity. In the USA 
approximately 20 % of emergency department visits for ADRs were due to antibiotics 
51
. In the 
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elderly antibiotics are the second most common class of drugs responsible for ADRs and have been 
implicated in fatalities 
52,53
.  
Costs 
There are both direct and indirect costs due to antibiotic prescribing. Used appropriately 
the direct cost of an antibiotic is both justified and appropriate. Total costs in Norway are 1.08 
billion Norwegian crowns and accounts for 8.7 % of the annual costs of medications prescribed in 
Norway. How much of this is due to inappropriate prescribing is difficult to estimate and several 
factors make a calculation difficult. First, laws of confidentiality make it impossible for the national 
registry of prescriptions to know the diagnosis for which an antibiotic is prescribed. Secondly, it is 
impossible to know exactly which portion of the antibiotic prescribing was warranted and which 
was unwarranted. As respiratory tract infections are the most common infections treated in primary 
care, improving prescribing for these conditions can result in substantial savings. Studies from the 
USA 
54
 and England 
55
 suggest that direct costs of unnecessary antibiotic prescriptions are over US 
$ 700 million and US $ 35-70 million respectively. The costs of office visits come in addition. 
Another area contributing to high rates of unnecessary antibiotic prescribing occurs in nursing 
homes 
56
 for viral RTI and asymptomatic bacteriuria (ASB). Here, conservative estimates suggest 
that 22 % of prescribed antibiotics were unnecessary
57
.  
The indirect costs due to minor side effects and work absence due to these exist but are 
more difficult to estimate. Another indirect cost is the medicalizing of future episodes of self-
limiting illnesses caused by the misunderstood belief held by patients treated with antibiotics that 
antibiotics are necessary
58
.  
 
 
6.8 Antibiotic stewardship 
―Stewardship: the conducting, supervising, or managing of something; especially: the careful and 
responsible management of something entrusted to one's care” Webster’s Dictionary 1 
6.8.1 Background 
Antibiotic stewardship programs (ASP) are necessary because antibiotic resistance development is 
inevitable and the development of new antibiotics is stalled. The goals of ASP are to promote 
rational antibiotic prescribing without compromising patient safety. Antibiotic stewardship is a 
continuous process with three key elements;  
1. Surveillance of antibiotic prescribing  
2. Surveillance of resistance development 
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3. Availability and implementation of reliable guidelines  
These elements are used in different strategies aimed at promoting rational drug prescribing. 
Rational empiric antibiotic prescribing entails choosing the most effective and safest antibiotic 
against the pathogenic microbe with the most limited impact on the normal flora. The most narrow-
spectrum antibiotic should be given in a sufficient dosage over an adequate time period, long 
enough to eradicate the pathogenic bacterium and as short as possible to limit the impact on the 
normal flora. It is therefore important to streamline empirical broad-spectrum therapy if the 
bacterium is susceptible to a narrow-spectrum antibiotic. 
The first step is to discern if the presenting complaint is due to an infectious etiology. 
Some of the most common presenting complaints in family medicine like cough, fever, or dysuria 
can be caused by non-infectious conditions. Secondly, if the etiology is presumably infectious, one 
needs to discern if the infectious agent is bacterial or viral.  If it is bacterial, one needs to discern if 
it is necessary to treat with antibiotics. In some infections the etiology may be mixed viral/bacterial 
and in many cases it is not feasible to determine the putative bacterial etiology. Regardless of 
etiology, for many infections there is a high likelihood that the condition is self-limiting. 
Unfortunately, diagnoses like cough, purulent rhinitis, and bronchitis are too often treated with 
antibiotics despite clear evidence that antibiotics have no clinically relevant beneficial effects 
59-61
.  
There are regional, institutional and individual differences in antibiotic prescribing with no 
obvious explanation for these differences. In Europe, this is illustrated by the marked differences in 
total antibiotic prescribing and the differences in the choice of antibiotics among countries 
22
. In 
Norway, this is illustrated by both the difference in antibiotic prescribing in nursing homes 
62
 but 
also between individual physicians 
63,64
. The use of rational antibiotic prescribing attempts to reduce 
these inexplicable differences. Surveillance of antibiotic use at the national, institutional and the 
individual levels generates the information necessary to identify areas for improvement.  
Most ASPs are aimed at improving inpatient antibiotic prescribing 
20,65,66
. While many of 
the components of ASP are relevant outside the hospital, they need to be tailored to address the 
unique characteristics of the nursing home and emergency department (ED) settings. Examples of 
these characteristics in the nursing home include multi-morbidity, polypharmacy, the role of non-
physician initiated diagnosis, and the high rates of telephone prescribing 
57
. In the ED, special 
considerations include consultation time constrain with high patient turnover, limited diagnostic 
resources and the challenge of patient follow-up. While there are some studies focusing on ASP in 
the nursing home setting, there are few studies specifically addressing the need for ASP in the ED 
67
.  
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6.8.2 Guidelines 
Despite commonplace examples of unnecessary antibiotic prescribing, the most important goal of 
antibiotic stewardship is identifying patients having a clear indication for empiric antibiotic therapy. 
Indeed, antibiotics used properly have a crucial role in treating infections and are an integral part of 
ASP. In Norway, there are national guidelines for empiric antibiotic prescribing in both the hospital 
and in primary care 
41,68
 (table 1). The recommendations in these guidelines are tailored to 
Norwegian antibiotic resistance patterns and evidence-based when possible. In addition to therapy 
recommendations, and recommendation for when not to use antibiotics, the guidelines include 
information on the proper use of diagnostic testing. Examples of these include judicious use of point 
of care testing in respiratory tract infections, and appropriate techniques in acquiring material for 
microbiologic analysis. 
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Infection Drug of choice 
Acute Otitis Media (AOM) 
Phenoxymethylpenicillin 
Adults:1.3 g x 3–4 x 5 d 
Children: 8–15 mg/kg 3–4 x 5 d 
Streptococcal tonsillitis 
Phenoxymethylpenicillin 
Adults: 660 mg x 4 x 10 d 
Children: 10mg/kg x 4 x 10 d 
Acute sinusitis 
Phenoxymethylpenicillin 
Adults: 0.66–1.3 g 3–4 x 7–10 d 
Acute bronchitis None 
Pneumonia 
Phenoxymethylpenicillin 
Adults: 1.3 g x 4 x 7–10 d 
Children: 15mg/kg x 4 x 7–10 d 
Uncomplicated cystitis: Otherwise 
healthy, non-pregnant women 15–60 
years of age 
Trimethoprim 160 mg x 2 or 300 mg x 1 x 1–3 d 
Nitrofurantoin 50 mg x 3 x3 d 
Pivmecillinam 200 mg x 3 x 3 d 
Complicated cystitis: Women > 60, 
men, children 
Adults: Trimethoprim 160 mg x 2 or 300 mg x 1x 5–7 d 
Nitrofurantoin 50 mg x 3 x 5–7 d 
Pivmecillinam 200 mg x 3 x 5–7 d 
Children: Trimethoprim 3 mg/kg x2 x 3–7 d 
Nitrofurantoin 1.5 mg/kg x 2 x 3–7 d 
Pivmecillinam 7.5 mg/kg x 3 x 3–7 d 
Pyelonephritis 
Adults: Trimethoprim-sulfa 8/400 mg, 2 x 2 x 7–10 d 
Pivmecillinam 400 mg x 3 x 7–10 d 
(Amoxicillin 500 mg x 3 x 7–10 d) 
Children :Trimethoprim sulfa 0.5 ml/kg x 2 x 7–10 d 
Pivmecillinam 10–15 mg/kg x 3 x 7–10 d (Amoxicillin 15–
20mg/kg x 3 x 7–10 d) 
Pregnant women with cystitis or 
asymptomatic bacteriuria 
Nitrofurantoin 50 mg x 3 x 7 d 
Pivmecillinam 200 mg x 3 x 7 d 
Trimethoprim 300 mg x 1 x 7 d 
Table 1. Recommendations for treating respiratory and urinary tract infections. An excerpt from 
:Antibiotic treatment in primary care concise version (reproduced with permission The Antibiotic 
Centre for Primary Care and The Norwegian Directorate of Health)
41
 
 
There are a several factors necessary for the development of high quality guidelines. The 
methodology behind the identification and evaluation of the studies providing the scientific basis 
for a guideline‘s recommendations must be both complete and transparent. The Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) 
69
 system is an 
internationally accepted system for developing guidelines. This system addresses not only the 
quality of the evidence base of a guideline but also the advantages, disadvantages and feasibility of 
specific recommendations. Although important in guideline development, it is not sufficient to 
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focus solely on the quality of the literature providing the basis of the guideline. This is especially 
relevant for infectious disease guidelines which cannot blindly adapt recommendations from other 
countries. Because the external validity of even high quality research abroad may be a serious 
limitation, the Norwegian guidelines have taken special consideration of Norwegian resistance data 
when preparing the guidelines.  
A thorough evaluation of a guideline needs to consider transparency, user involvement, 
and an evaluation of implementation. The Appraisal of Guidelines for Research and Evaluation 
(AGREE) Instrument 
70
 evaluates the process of practice guideline development including 
implementation and considers all these issues in scoring the overall quality of the guideline. It is 
divided into 23 criteria organized into 6 quality domains; scope and purpose, stakeholder 
involvement, rigor of development, clarity of presentation, applicability, and editorial 
independence. The NGAPC have been evaluated with the AGREE instrument and received a 
relatively high score of 78/92 (personal communication, the Norwegian Electronic Health Library). 
 
 
6.8.3 Interventions to improve antibiotic prescribing 
Interventions to improve antibiotic prescribing aim to reduce inappropriate antibiotic prescribing 
and to encourage use of narrower spectrum antibiotics instead of broad spectrum antibiotics when 
possible. Interventions can be directed at the general public, patients, physicians or a combination 
of these groups 
71. Changing physicians‘ antibiotic prescribing behavior is, however, a challenge. 
Several modalities to attempt this task are available. Examples include printed guidelines issued by 
public health authorities, continued medical education (CME) courses, use of delayed prescribing, 
economic incentives and restrictions 
66,72
. Several factors are important to improve physicians‘ 
antibiotic prescribing behavior 
73
. In general, interventions such as academic detailing aimed at 
physician education appear effective 
74
. However, no single type of intervention is universally 
effective and some interventions are relatively ineffective 
75
. The best results are based on a 
combination of interventions 
76
.  
Previous Norwegian interventions have demonstrated significant improvement in antibiotic 
prescribing in the ED 
77,78
 and in the hospital
79
. A recent Norwegian study showed that a peer-group 
based intervention reduced total antibiotic prescribing for respiratory tract infections and increased 
the proportion of first choice antibiotic penicillin G in favor of broad spectrum antibiotic 
prescribing
80
.  
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Another type of intervention is the delayed prescription strategy. This approach utilizes a 
prescription given to a patient who does not need antibiotic treatment at the time of consultation but 
may need antibiotics if the condition worsens 
81
. This enables the patient to initiate antibiotic 
treatment without the need for re-consultation. Critics have nonetheless pointed out that these 
reductions are disappointing low in comparison to simply not prescribing when there is no 
indication for antibiotics 
81,82
. Restrictions on prescribing are another strategy employed in ASP 
66,83
. Although not always popular among physicians, restrictions can reduce unnecessary antibiotic 
prescribing without increasing complications 
84,85
. Restrictions have the added advantage of 
sustained improvement of antibiotic prescribing which can be a problem with other types of 
interventions 
83,86
.  
For UTI there is less evidence that interventions reduce unnecessary treatment. This may 
be due to several factors. The majority of UTIs are uncomplicated cystitis for which antibiotic 
therapy is clearly effective and greatly appreciated by the patients. In addition the course of therapy 
for uncomplicated UTI is short making the contribution to total antibiotic usage less than infections 
requiring longer treatment duration. Studies therefore focus on improving the choice of antibiotic 
therapy 
87
. In contrast to uncomplicated UTI, there is a clear need to improve diagnosis and therapy 
of UTI in the institutionalized elderly. UTI tract infections are the most commonly treated infection 
in nursing homes both in Norway and abroad
57,88-90
. Several factors including the high rate of 
cognitive impairment, misinterpretation of unspecific symptoms, and inappropriate use of 
diagnostic tests make the diagnosis of UTI in this patient group challenging and contributes to 
unwarranted antibiotic prescribing 
56,91,92
. Overprescribing in the elderly is especially disconcerting 
due to increasing the risk of toxicity, drug interactions and antibiotic resistance in population 
46
.  
 
6.9 The settings of these studies 
Both the ED and the nursing home (NH) are arenas in which focus on rational antibiotic prescribing 
is important for several reasons. The rapidly expanding elderly population in the western world will 
result in an increasing need for assisted care institutions including NHs. During past 30 years the 
Norwegian population 80 years and older has more than doubled. There are approximately 900 NHs 
with over 40 000 beds in Norway, three times the number in 1970
93
. The average age of a patient in 
a Norwegian NH is 84 and approximately 75 % are women. Reduced cognitive function among 
Norwegian NH residents is approximately 60-75 % 
94,95
. Morbidity in addition to dementia is a 
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problem reflected by the high use of medications in these patients. Studies indicate that Norwegian 
NH patients use 6-12 medications daily with a substantial risk of adverse drug interactions
96,97
.  
The terminology referring to assisted care facilities is varied, reflecting the heterogeneity 
of the patients residing in these institutions. In this thesis the term nursing home refers to an 
institution where skilled nursing care is available 24 hours a day.  
There is a growing use of ED services in Norway and abroad
98,99
. In Norway there are 
approximately 150,000 ED consultations annually with respiratory tract and urinary tract infections 
among the five most common registered diagnoses every year 
99
. The ED service is integrated in 
primary care in Norway and is not hospital based. It is available from 3 PM-8 AM daily and 24 
hours daily during the weekend throughout Norway. The unique characteristics of these two settings 
makes extrapolation of results from hospital based studies problematic.  
This thesis aims to explore ways to improve antibiotic prescribing in these two Norwegian 
primary care settings. 
7 This Thesis 
7.1 Aim 
The aim of this thesis is to examine specific target areas for improved antibiotic prescribing in selected 
primary care settings by:  
1. Evaluating the indication for ciprofloxacin prescribing and the extent of microbiologic 
diagnostic work-up prior to prescribing. 
2. Evaluating the degree to which antibiotic prescribing in the nursing home is in accordance 
with the national guidelines. 
3. To see if differences in resistance rates of uropathogens isolated from nursing home patients 
compared to elderly patients living at home warrant separate empiric antibiotic therapy 
recommendations for urinary tract infections. To see if empiric antibiotic therapy 
recommendations for UTI in the elderly based on gender are warranted. 
4. To see if a simple intervention can reduce ciprofloxacin prescribing in an emergency 
department.  
 
7.2 Material and Methods 
7.2.1 Paper I: Fluoroquinolone study 100 
Design: Cross-sectional retrospective study. 
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Population: Nursing home patients in Adrenal municipality prescribed a fluoroquinolone 
during a one year period. 
Main outcome measures. The proportion of patients diagnosed with some form of 
microbiologic work up. Culture and resistance results for these patients.  
Method: We identified all patients prescribed a fluoroquinolone by specifying the 
Anatomical Therapeutic Chemical Classification code (ATC) 
101
 in the Gerica® electronic patient 
record system (EPR) for the time period 1.12. 2006 to 30.11.2007. This generated a list of all 
patients prescribed ciprofloxacin (J01MA02) or ofloxacin (J01MA01). We searched the patients‘ 
records and recorded the following; patient age, gender, ward type (long-term or short term), 
indication, dosage, duration, and prescribing physician. Discharge summaries for patients initially 
treated at the local hospital were reviewed for all patients in whom initiation of antibiotic treatment 
occurred at the local hospital. We then contacted the microbiologic laboratory for culture and 
resistance results for all these patients.  
Statistics. The data were published without formal statistical analysis.  
Approval. The study was evaluated as a quality assurance project by the Regional Ethics 
Committee (6.2008.1602) and by the Norwegian Data Protection Authority. 
  
7.2.2 Paper II: Compliance study 
88
 
Design. Descriptive cross-sectional retrospective study.  
Population. Nursing home patients in Arendal municipality who were prescribed 
antibiotics in a one year period.  
Main outcome measures. Choice of antibiotic in respect to the recommendations in the 
national guidelines for antibiotic prescribing. 
Method. We used the ATC system to search Gerica® for all patients prescribed antibiotics 
during the 12 month period from 01.03.07-28.02.08. We searched the patients‘ medical records and 
recorded the following data; age, gender, ward (short-term vs. long-term), name of and indication 
for antibiotic, dose and duration of antibiotic treatment, the prescribing physician (nursing home, 
emergency call service (ECS), or hospital. Antibiotic use is measured as DDD per 1000 bed days. 
We calculated this by totaling DDD used in one year divided by the total number of nursing home 
beds x 365 and multiplying this by 1000.  
Prevalence is calculated by the total number of days antibiotics were prescribed divided by the total 
number of beds x 365. 
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The national guidelines for antibiotic prescribing 
102
 have specific recommendations for empiric 
therapy for all common bacterial infections in the primary care setting. Deviation from the 
guidelines was defined as choice of antibiotics not in accordance with these recommendations. 
Statistics. We used Pearson‘s chi-squared test to test for associations between the 
proportions of antibiotics prescribed according to national guidelines vs. proportion not in 
accordance with guidelines, and which ward patients were on (long-term vs. short-term ). We 
calculated odds ratios (OR) and 95 % confidence intervals (95 % CI) to test for the association 
between type of prescribing physician, or type of ward with compliant prescribing.  
Approval. The study was approved by the Regional Ethics Committee (2010/726a).  
7.2.3 Paper III: Uropathogen resistance study  
Design. Retrospective cross sectional study. 
Population. Positive urine cultures from patients in nursing homes in a twelve month 
period were susceptibility tested and compared to positive urine cultures from non-hospitalized 
patients 65 years or older living at home.  
Main outcome measures. Bacteria responsible for urinary tract infections and their 
antimicrobial resistance rates.  
Method. Urine cultures fulfilling the criteria for significant bacteriuria (> 10,000 colony-
forming units/ml urine) were included in the study. Appropriate antibiotics for resistance testing 
were selected for each bacterial species according to recommendations from the Norwegian 
Working Group on Antibiotics (NWGA). Results were interpreted according to clinical breakpoints 
from NWGA which are based on those from The European Committee on Antimicrobial 
Susceptibility Testing (EUCAST). Resistance values were recorded either as susceptible (S), 
intermediate (I), or resistant (R).  
Antibiotic resistance patterns from patients living in nursing homes were compared to resistance 
patterns from patients living at home. Resistance patterns from males were compared to results 
from females irrespective of where they lived.  
Statistics. We used Pearson's chi-squared test to compare differences in gender distribution 
between the study group and the community dwelling (CD) group and the t-test for independent 
samples to compare the mean age in the two groups. 
We used the Pearson‘s chi-squared test and the Fischer‘s exact test (when appropriate) to compare 
differences in resistance rates for relevant antibiotics between the study group and the CD group, 
and between males and females. 
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Approval. The study was approved by the Norwegian regional ethics committee (REK 
sør-øst 2013/2282). 
 
7.2.4 Paper IV: Intervention study 
103
 
Design. Prospective non-randomized cluster control trial. 
Population. Emergency department (ED) physicians prescribing antibiotics for urinary 
tract infections. 
Main outcome measures. Antibiotic prescribing for UTIs. 
Method. All antibiotic prescribing for UTIs was registered one year prior to and one year 
after the intervention in two different EDs. One ED received the intervention while the other ED 
served as control. Both EDs were located in southeast Norway, an area with similar resistance 
patterns, and served a demographically nearly identical population of approximately 100,000. Both 
EDs had approximately 40000 consultations annually.  
The intervention had two components: Removing ciprofloxacin from the ED formulary and 
introducing a therapy suggestion list for antibiotic use accompanying all urine dipstick results.  
Statistics. Frequencies of antibiotic prescribing were analyzed by means of a logistic 
regression model. Dependencies in the data, due to clustering at the physician level, were handled 
by Generalized Estimating Equations (GEE) with unstructured working correlation and robust 
variance estimation. 95 % confidence intervals were used. 
Approval. The study was approved by the regional ethics committee (Project number 
REK:6.2008.1602). 
8 Summary of results 
8.1 Paper I: Fluoroquinolone study  
78 nursing home patients received 94 ciprofloxacin prescriptions. Eleven of these patients were treated 
with ciprofloxacin more than once. No patients were treated with ofloxacin. 51 of the prescriptions were 
for patients on the long-term wards (315 beds) while 43 of the prescriptions were for patients on the 
short-term wards (45 beds). Of the 94 prescriptions 72 (77 %) were for women and 22 (23 %) for males. 
The mean age was 86 for women and 76 for men. There was no statistically significant difference in 
gender (73 % vs 81 %, p=0.31) or age (84.3 vs 83.6, p=0.68) between the patients treated on the long-
term vs the short-term ward. 
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On the long-term wards the indication for ciprofloxacin prescription was UTI in 78 % of 
the cases, respiratory tract infection (RTI) in 4 %, mixed UTI/RTI in 6 %, and in 12 % for other 
infections. On the short-term wards the indication was UTI in 40 % of the cases, RTI in 37 %, 
mixed UTI/RTI in 7 %, and 14 % for other infections. There was a statistically significant 
difference in indication for ciprofloxacin prescribing between the two ward types (p< 0.05). 
On the long-term ward nursing home physicians wrote 84 % of the prescriptions, hospital 
physicians wrote 10 % and physicians in the emergency department (ED) wrote 6 %. On the short-
term ward nursing home physicians wrote 33 % of the prescriptions, hospital physicians wrote 62 % 
and physicians in the emergency department wrote 5 %. There was a statistically significant 
difference in prescribing physician affiliation between the two ward types (p< 0.05). 
Microbiologic diagnostics were performed in 51.8 % of treatments initiated by a nursing home 
physician, 51.5 % initiated by a hospital physician and in 20 % initiated by an ED physician. There 
were 36 positive cultures. Of these 36, twelve were caused by a bacterium which was solely 
susceptible to ciprofloxacin.  
 
8.2 Paper II: Compliance study  
The total antibiotic prescribing was for 714 infections in 327 NH patients which translates to 55 
DDD/1000 bed days. The overall prevalence of patients receiving antibiotics was 6.6 %, with the 
long-term wards having a prevalence of 5.6 %, while the short-term wards having a prevalence of 
11.2 %. UTI was responsible for 53 % of the infections, followed by RTI responsible for 21 %, and 
skin and soft tissue infections (SSTI) responsible for 14 %. Combined UTI/RTI or other infections 
were responsible for 5 %.  In 8 % no documentation for the infection was found in the patients‘ 
records.  
73 % of prescribing was by nursing home physicians, 17 % by physicians at the county 
hospital, 7 % by the doctor on call in the ED, and 3 % by the patients‘ family doctor. It was more 
likely that a non-nursing home physician was the prescribing physician for patients on the short-
term ward than on the long-term ward (OR 4.39, 95 % CI 3.09- 6.24). 
The most commonly prescribed antibiotics; trimethoprim, pivmecillinam, ciprofloxacin 
and penicillin V accounted for 61 % of total prescribing. 77 % of the prescriptions for UTI, 79 % 
for RTI, and 76 % for SSTI were in compliance with the guidelines. Ciprofloxacin and cephalexin 
accounted for 85 % (114/134) of the prescriptions not in compliance with the national guidelines. 
When comparing the proportion of antibiotics prescribed according to national guidelines, there was 
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a tendency of higher non-compliant prescribing on the short-term as compared to the long-term 
ward (OR 1.41, 95 % CI 0.95 - 2.1, p= 0.09). 
 
8.3 Paper III. Uropathogen resistance study  
E coli was the most common bacteria in both the nursing home group and in the CD group (64 % 
vs. 64 %) followed by E faecalis (10 % vs. 8 %) with no significant difference between the two 
groups a whole (p = 0.454).  
In the nursing home group there were significantly higher resistance rates to ciprofloxacin for K 
pneumoniae (18 % vs. 3 %; p = 0.016) and P mirabilis (25 % vs. 5 %; p = 0.011).  
E  coli was significantly more common in females than males (70 % vs. 39 %; p < 0.05), while E 
faecalis was significantly more common in males than females (18 % vs. 7 %; p < 0.05). 
For males there was a significantly higher resistance rate to ciprofloxacin for E coli than for females 
(12 % vs. 7 %; p = 0.016) and to mecillinam for P mirabilis (12 % vs. 3 %; p = 0.036). 
 
8.4 Paper IV Intervention study  
Baseline demographics were nearly identical in the intervention ED and the control ED. The 
intervention ED had 14 % more UTI diagnoses than the control ED. The relative frequencies of 
cystitis and pyelonephritis before and after the intervention were similar in both EDs. In the 
intervention ED there were 1286 cystitis and 107 pyelonephritis diagnoses pre-intervention, with 
1264 and 73 respectively post-intervention. In the control ED there were 1103 cystitis and 113 
pyelonephritis diagnoses pre-intervention, with 1091 and 90 respectively post-intervention.  
Between 86-89 % of cystitis diagnoses were treated in both the intervention and the control 
EDs both pre- and post-intervention. In the intervention ED ciprofloxacin prescribing decreased 
from 6.3 % of the cases pre-intervention to 3.4 % post intervention. In the control ED ciprofloxacin 
prescribing increased from 2.3 % pre-intervention to 4.7 % post-intervention. This significant 
decrease in prescribing of ciprofloxacin (p<0.05) in the intervention ED was accompanied by a 
significant increase in pivmecillinam prescribing (p=0.042).  
There was no significant change in ciprofloxacin prescribing for pyelonephritis in either 
ED. Prescribing rates for pyelonephritis were higher in the intervention ED than in the control ED 
pre-intervention (15.9 % versus 8.0 % respectively) and remained higher post intervention (15.1 % 
versus 5.6 %). 
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9 Discussion  
9.1 Summary 
Adequate microbiologic diagnostic work up prior to empiric therapy with ciprofloxacin in the 
nursing home setting is often lacking. This is especially true when ciprofloxacin is prescribed off-
hours by a physician in the ED. Pre-therapy diagnostic work up by nursing home physicians and by 
hospital physicians is better than ED physicians. Nonetheless, only half of nursing home patients 
treated with ciprofloxacin had their urine (or blood) cultured. The potential to reduce unnecessary 
ciprofloxacin treatment duration is substantial with adequate pre-therapy diagnostics. 
Antibiotic prescribing in the nursing home often complies with the national guidelines. 
There are, however, certain aspects of the prescribing which need improvement. In terms of 
antibiotic choice, ciprofloxacin prescribing for RTI and UVI, cephalexin for UVI and SSTI, and 
doxycycline treatment for RTI are specific targets for improvement. It seems that prescribing on 
short-term wards comply less with the national guidelines than on long-term wards. As there is a 
higher percentage of non-nursing home physicians responsible for prescribing on the short-term 
wards, efforts to improve compliance must target the nursing home, the hospital and the ED.  
Compared to elderly patients living at home, the elderly living in the nursing homes do not 
have significantly different bacteria responsible for their UTI, nor are these bacteria more resistant. 
There are, however, significant differences in the bacterial etiology and the resistance patterns of 
bacteria causing UTI in men compared to the bacteria causing UTI in women. These differences 
may need to be considered in national guidelines for treating infections in the elderly. 
UTIs are one of the most common diagnoses made in the ED making it a target for 
optimizing empiric antibiotic therapy. A simple intervention combing a therapy suggestion list with 
removal of ciprofloxacin from the local formulary reduced unnecessary ciprofloxacin prescribing 
while increasing appropriate pivmecillinam prescribing. Potentially appropriate ciprofloxacin 
prescribing for pyelonephritis remained unchanged. 
 
9.2 Internal validity of these studies 
Success is going from failure to failure with no loss of enthusiasm. (Winston Churchill) 
9.2.1 General considerations 
A study‘s internal validity refers to how well a study avoids systematic bias, reflecting the quality 
of the study‘s methodology. There are a number of factors relevant when evaluating the internal 
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validity of medical research. Internal validity is a prerequisite for a study‘s external validity which 
will be discussed later in this thesis.  
The first three papers were retrospective cross sectional studies. There are inherent biases 
and strengths in retrospective studies. One weakness is the lack of randomization. The patient 
population is predefined. It is therefore difficult to know how representative the study population is 
for the problem one is researching. In three of these papers the nursing home was the setting of the 
study, and the patients were all treated with antibiotics. The gender distribution was 80 %, 73 %, 
and 79 % females in each of the studies respectively. This gender distribution is similar to other 
studies from European and North American NH studies 
57,89,104
 .  
Papers I and II included all patients receiving an antibiotic while the third paper restricted 
inclusion to patients 65 years or older. Despite this, the ages in the studies are similar. In paper I, 
the mean age was reported by the ward on which the patient resided and was 84 years for both the 
long-term ward and the short-term ward. In paper II median age was 87 for females and 82 for 
males. In paper III the respective mean ages were 87 vs 83. Optimally we should have consistently 
used either the median or the mean to describe the midpoint of our populations‘ ages. The age range 
in our papers is also in line with studies from other European and North American NH studies 
57,89,104
.  
9.2.2 Methodology: database generation  
Recall bias is a problem in retrospective studies. These papers are based on what was 
documented and not necessarily what was actually done. In the three papers from the nursing 
homes, the defining inclusion-criteria was an antibiotic prescription. In the papers I and II, the 
nursing homes used the electronic patient journal system (EPJ) system Gerica®. The prescription 
module in Gerica® allowed us to generate a list of all patients receiving an antibiotic in a given 
time period. Gerica® does not, however, automatically require a physician designated diagnosis or 
diagnosis code (e.g. ICPC or ICD) before prescribing an antibiotic. If Gerica® had this function it 
would have been relatively easy to cross reference an antibiotic prescription with the diagnosis code 
generating a list in which each antibiotic prescription was linked to a specific diagnosis. This 
technique has been used in other studies and was used in paper IV in this thesis 
80
. In paper IV the 
EPJ used in the participating EDs was WinMed®. In contrast to Gerica®, WinMed requires a 
physician to specify an ICPC diagnosis every time a physician writes an entry in a patients‘ journal.  
While the relative ease in generating a diagnosis-prescription linked list is an apparent 
advantage, there are disadvantages with this approach also. The physician generated diagnostic 
ICPC code does not necessarily reflect the content of text in the actual EPJ entry. In certain cases it 
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can be directly misleading. One example of this is seen in table II in paper IV where 33-41 % of 
patients with pyelonephritis and 11-14 % of patients with cystitis received no antibiotic treatment. 
This illogically high rate of no-treatment was seen in both EDs and in both observation periods. It 
also seemed illogical that a lower percentage of patients with pyelonephritis received antibiotics 
than patients with cystitis. To control for this we read all EPJ notes for patients not receiving 
antibiotics for both pyelonephritis and cystitis. Nearly all patients not receiving antibiotics for 
pyelonephritis were admitted to the hospital for treatment. This was the case in both EDs in both 
periods. For cystitis the majority of patients receiving no treatment were patients with questions 
about treatment, side effects, or advice about prophylaxis. This ancillary information would remain 
hidden in a database generated solely by an electronic extraction of ICPC diagnosis codes alone.  
In papers I and II we had to read all journal entries for each antibiotic prescribed to 
determine the type of infection being treated because Gerica® could not generate a reliable 
diagnosis-prescription list. In these nursing homes there is no systematic use of diagnostic tools like 
the Loeb or McGeer criteria when evaluating patients having an infection 
105,106
. Physicians‘ and 
nurses‘ written documentation was the basis for how we determined the type of infection. In the 
most extreme cases, there was so little information in the patients‘ records that it was impossible to 
specify the gross anatomical localization of the infection (RTI, UTI, SSTI, other). These cases were 
classified as unspecified infections and were responsible for about 8 % of the results in both papers. 
For the same reason we were not able to be more specific within an anatomical diagnostic group. 
Cystitis was grouped with pyelonephritis and asymptomatic bacteriuria (ASB) as UTI, bronchitis 
with pneumonia and COPD exacerbations as RTI, and cellulitis with decubitus as SSTI. 
 
9.2.3 Selection bias urine sampling  
Selection bias can influence the results of a study if the groups being compared are dissimilar. 
There are several possible dissimilarities in urine collection which may bias the results in paper III. 
The control group, though similar in gender distribution, was ten years younger than the NH group. 
The prevalence of resistant organisms in urine cultures increases with age 
107-110
. We found no 
increase in resistance with age which may strengthen the validity of the observed results. In the 
control group we did not know the reason for urine culturing while in the NH group all urines were 
from patients treated for a suspected UTI. There were no post-therapy urine cultures in the NH 
group raising the potential for a difference in the contribution of post-therapy control urines in the 
two groups. Although Norwegian guidelines specifically dissuade urine culture for ASB 
41
, the 
relative contribution of ASB in the two groups is unknown. It is known than non-specific symptoms 
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can result in inappropriate urine dipstick testing which is then inappropriately interpreted as a 
treatment requiring UTI. This type of misinterpretation may be more common in NH patients than 
in patients living at home. How inequities in the contribution of ASB and post-therapy controls 
would affect the validity of the observed results is difficult to know.  
We did not know what percentage of the urine cultures were from patients with urinary 
catheters in either group. It is possible that there was an unequal prevalence of catheter specimens 
between the two groups. There is a higher prevalence of urinary catheter use in patients residing in 
NH 
111
 and urines cultured from patients with catheters have a higher rate of resistant organisms 
112,113
. The potentially higher rate of catheters in the NH group would be expected to result in higher 
rates of resistant organisms in this group. Our results showed no higher resistance rates in the NH 
group.  
Although there are guidelines for urine sampling in Norway 
114
, adherence to these 
guidelines may differ between the NH and the CD groups. As patients in the CD group were 
younger and living at home it is possible that the percentage of mid-stream urine sample was higher 
in the CD group. Again, it is difficult to know how this possible bias contributed to our results 
showing no difference between the two groups.   
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9.3 Inappropriate vs non-compliant prescribing  
9.3.1 UTI  
Antibiotics may be inappropriate to use even when the choice of antibiotic is in compliance with the 
national guidelines. This is exemplified by antibiotic prescribing for ASB. The problem of 
antibiotic treatment of ASB in the nursing home is both widespread and challenging. There is clear 
evidence that treating ASB is neither effective at eliminating bacteriuria nor improving clinical 
outcome of patients 
115
. Furthermore, non-specific symptoms are often inappropriately interpreted 
as being due to a UTI 
92
. As both ASB and non-specific symptoms are prevalent in nursing home 
patients this contributes to misleading urine dipstick testing and urine culture which in turn leads to 
inappropriate antibiotic prescribing. Antibiotic treatment of ASB contributes significantly to 
inappropriate antibiotic prescribing in the NH 
56
.  
Unfortunately not being able to differentiate between the diagnoses within the anatomic 
diagnostic group makes it difficult to evaluate how much of the total prescribing was inappropriate. 
Nonetheless, total antibiotic prescribing is associated with increased resistance problems making 
reduction or elimination of antibiotic prescribing for ASB an important target for improvement. 
Unfortunately, incomplete and unsystematic documentation in patient records made it impossible to 
reliably determine how much of the total prescribing was due to ASB.  
In contrast to ASB, antibiotics are indicated for both cystitis and pyelonephritis but the 
choice of antibiotic may be inappropriate. Neither ciprofloxacin nor cephalexin is recommended for 
empiric treatment of cystitis in the NGAPC (table 2). In the guidelines, ciprofloxacin is only 
recommended in definitive treatment based on a culture result in which the isolated bacteria is only 
susceptible to ciprofloxacin. It is possible that some of the ciprofloxacin prescribing in paper II was 
based on culture results and therefore may be appropriate. The database in paper II came from the 
same NHs as in paper I making it unlikely that treatment based on culture results are higher than 
they were in paper I. The results in paper I demonstrated that only 50 % of the patients treated with 
ciprofloxacin had a culture result, and only 12 % had a microbe solely susceptible to ciprofloxacin. 
Cephalexin is not listed in the national guidelines as a therapeutic option in the treatment for either 
cystitis or pyelonephritis. In addition, susceptibility determination for cephalosporins is not 
routinely reported by the microbiology laboratories used by the NHs in these papers.  
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Infection Empirisk behandling Duration  
Uncomplicated 
lower urinary 
tract infection 
Pivmecillinam 200 mg x 3 
7 days for women  
14 days for men 
Trimethoprim 160 mg x 2 
Nitrofurantoin 50 mg x 3 
Amoxicillin 250 mg x 3* 
Cefalexin 250 mg x 3* 
Upper urinary 
tract infection 
Pivmecillinam 400 mg x 3 
7-14 days for 
both genders 
Trimethoprim-sulfamethoxazole 160+800 mg (2 
tabl./20 ml mixture) x 2 
Ciprofloxacin 500 mg x 2 
Ofloxacin 400 mg x 2 
 
Table 2. Recommendations for treating urinary tract infections.in nursing home patients. 
Adapted from: Antibiotic treatment in primary care (reproduced with permission The 
Antibiotic Centre for Primary Care and The Norwegian Directorate of Health41) 
* Only when culture results show resistance to all other antibiotics 
 
One interesting and arguably inappropriate finding in papers I and II was the low 
prescribing rates of nitrofurantoin for UTI. Cystitis is a much more common diagnosis in both the 
nursing home and in the emergency room than pyelonephritis. There is, therefore, no logical 
explanation for physicians prescribing nitrofurantoin so infrequently. In paper IV, E coli and E 
faecalis were the two most commonly isolated bacteria. Both bacteria are highly susceptible to 
nitrofurantoin in Norway 
34
. The contraindications for use of nitrofurantoin are limited. The 
NGAPC dissuade use of nitrofurantoin in patients with renal insufficiency because the 
concentrations of nitrofurantoin in the bladder are dependent on renal excretion and decreased renal 
clearance may cause toxicity 
41,116
. One might suspect that renal insufficiency with concomitant risk 
of toxicity in the elderly might be part of the reason for not prescribing nitrofurantoin in the NH 
setting. However, the prevalence of renal insufficiency in the elderly is not so high to explain that 
nitrofurantoin is used in only six percent of UTIs (table I in paper II). The low rates of 
nitrofurantoin prescribing for cystitis in the ED are clearly not due to the prevalence of renal 
insufficiency in this much younger and ostensibly healthier population (table II in paper IV). 
Previous randomized controlled studies show that nitrofurantoin is equally effective and no more 
toxic than other antibiotics in the treatment of cystitis 
117
. Other countries report various rates of 
nitrofurantoin prescribing in both the NH setting and for uncomplicated UTI 
104,118,119
. Dosing 
frequency alone doesn‘t seem to be the explanation as mecillinam, the most frequently prescribed 
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antibiotic, is also taken three times daily. It is not possible to explain why physicians in two 
completely different clinical settings had such low nitrofurantoin prescribing rates.  
Why mecillinam and trimethoprim dominate prescribing practice in both the NH setting 
and in the two EDs is difficult to explain. The prescribing physicians‘ fear of resistance problems 
cannot explain this practice, especially in the case of trimethoprim. In Norway, both E coli and E 
faecalis have resistance rates for trimethoprim near or above 20 % 
34
 making trimethoprim a less 
logical choice than nitrofurantoin for the treatment of cystitis. That nitrofurantoin cannot be 
prescribed for pyelonephritis does not explain the low prescribing rates as cystitis is a much more 
common diagnosis than pyelonephritis.  
 
9.3.2 RTI  
As with UTI, there is a parallel situation with diagnostic imprecision of RTI in these papers. 
Differentiating a self-limiting RTI from a lower RTI that needs antibiotic treatment is challenging. 
In the outpatient population this contributes to a high rate of unnecessary antibiotic use for 
bronchitis despite clear evidence that antibiotics are not necessary 
61,120,121
. Making this 
differentiation is more challenging in cognitively impaired elderly with a high rate of atypical 
presentations. Even the use of point of care testing with CRP and consistent documentation of the 
results would not provide irrefutable basis for a definitive diagnosis. Compounding this with a lack 
of specific diagnostic criteria prior to treatment resulted in our grouping several diagnoses together. 
In both papers I and II pneumonia, exacerbation of COPD, bronchitis and cough with fever were 
grouped as RTI when patients were treated with antibiotics.  
While antibiotics can be indicated for both pneumonia and exacerbations of COPD they 
are not appropriate for bronchitis or unspecific cough with fever. Inappropriate antibiotic 
prescribing for viral RTI, like inappropriate antibiotic prescribing for ASB, contributes significantly 
to overuse of antibiotics 
57
 
18,122
.  
A unique and challenging assessment of appropriate antibiotic therapy arises when 
evaluating treatment of pneumonia in debilitated, severely cognitively impaired elderly, or in the 
elderly who develop a respiratory infection while terminally ill 
123,124
. We did not systematically 
address antibiotic prescribing in the last days of patients‘ lives. The degree to which this practice 
contributes to resistance development is overshadowed by the ethical considerations in palliative 
treatment in these patients. Nonetheless, discussion with patients‘ relatives and good palliative 
routines on nursing home wards specifically addressing antibiotic use could avoid subjecting these 
patients to unwarranted antibiotic treatment.  
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Although these studies could not evaluate what proportion of the total antibiotics was 
prescribed inappropriately for viral RTI infections, we were able to evaluate whether the choice of 
the antibiotic was in line with NGAPC (table 3). Phenoxymethyl penicillin is the first line 
recommendation for pneumonia with doxycycline as an alternative in the case of penicillin allergy 
or difficulty swallowing. Despite this, doxycycline is prescribed 1.3 times more frequently than 
penicillin. Reports of the incidence of penicillin allergy in the general population vary, but true 
penicillin allergy (Type 1) is very rare and cannot explain why doxycycline is prescribed more often 
than penicillin
50,125
. While not inappropriate, the high prescribing rate of doxycycline may illustrate 
that guidelines alone will not dictate the choice of antibiotic. Issues such as convenience of 
administration may also play a role. Fortunately the macrolides with long half-lives, clarithromycin 
and azithromycin were rarely prescribed.  
 
Empiric treatment Antibiotic dosage Duration  
First Choice Phenoxymethylpenicillin 660 mg -1,3 g x 4 7-10 days 
Alternative choice 
Doxycycline 100 mg x 1 
7-10 days 
Amoxicillin 500 mg x 3 
Erythromycin enterocapsle 250 (500) mg x 4 
Erythromycin ES 500 (1000) mg x 4 
Clarithromycin 250-500 mg x 2 
Azithromycin 500 mg x1 3 days 
Special indications* 
Trimethoprim-sulfamethoxazole 160+800 mg (2 
tabl/20 ml mixture) x 2 7-10 days 
Ciprofloxacin 500 mg x 2 + 
Phenoxymethylpenicillin 0,65-1.3 x 4 7-10 days 
 
Table 3. Recommendations for treating pneumonia.in nursing home patients. Adapted 
from: Antibiotic treatment in primary care (reproduced with permission The Antibiotic 
Centre for Primary Care and The Norwegian Directorate of Health)
41
.  
* Empiric treatment shortly after hospital discharge or when culture results show resistance 
to first and alternative choice antibiotics 
 
As in the case with UTI, ciprofloxacin was the most frequently prescribed antibiotic not in 
compliance with the national guidelines. The use of ciprofloxacin in RTI is even less reasonable 
than in UTI. S pneumoniae is the most common bacterial etiology for RTI. In Norway at the time of 
this study, pneumococcal resistance to penicillin was < 1 % making the choice of ciprofloxacin for 
RTI indefensible 
28
.  
Ciprofloxacin was also the most commonly prescribed antibiotic in patients with a 
presumed combined UTI/RTI and in patients with no specified infection. There are no specific 
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recommendations for empiric therapy for infection of unknown etiology in the NGAPC. Although 
this makes evaluating compliance with guidelines a moot point, it does not make the issue of 
appropriate treatment in these cases irrelevant. Infections in the elderly often pose a diagnostic 
challenge. Delirium can be the presenting sign of an infection even in the cognitively well-
functioning elderly. Even more challenging is the worsening of cognitive function in cognitively 
impaired patients with non-specific symptoms. Infection can be the cause, but localization of the 
cause may be less obvious. Both of these situations illustrate another potentially inappropriate 
aspect of antibiotic treatment not evaluated in these studies; missed diagnosis with inappropriate 
underuse of antibiotics. A systematic evaluation of these patients is necessary to discern infectious 
from non-infectious cause of their mental deterioration 
126
. 
Acute deterioration due to a possible infection of unknown etiology in an otherwise well-
functioning elderly patient is an example of an appropriate indication for antibiotic prescribing. It is, 
therefore, worth evaluating specific recommendations in the guidelines for the treatment of 
infections with unknown or uncertain etiology in the NH setting. The therapy suggestions need to 
cover UTI, RTI and more elusive and uncommon diagnoses such as cholecystitis and diverticulitis. 
Balancing effectiveness, toxicity, risk of interactions and contribution to resistance development in 
mind, possible alternatives include amoxicillin and trimethoprim-sulfa.  
 
9.4 Advantages of the retrospective studies  
An advantage of observational retrospective studies is that they often reflect routine clinical practice 
which is not necessarily the case with controlled prospective studies. This retrospective design was 
essential in the first two papers. Both studies aimed to evaluate the quality of real life clinical 
practice. Being observed would introduce bias as prescribing behavior is likely to be affected and 
often times improved by the observation process, the so called Hawthorne effect 
127
. In paper I, it 
would be difficult to assess how prospective documentation and registration of diagnostic practice 
would affect physicians‘ diagnostic behavior prior to ciprofloxacin prescribing. Registering how 
often physicians ordered culturing prior to ciprofloxacin prescribing might lead them to increase the 
frequency of testing. Physicians might consciously or sub-consciously choose alternative antibiotics 
if even a slightly more time-consuming process was coupled to ciprofloxacin prescribing alone, 
especially when the study occurred over one year. Similarly, in the second paper, a prospective 
design would increase the possibility of physicians being aware that their antibiotic prescribing was 
being registered which could bias them to prescribe in accordance with guidelines.  
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One might circumvent the potential bias of being observed by blinding the physicians to 
the process. This raises the important issue of informed consent and cost. Both studies were 
evaluated by the regional ethics committee and deemed to be quality control studies. In paper I all 
nursing home physicians caring for the patients treated with ciprofloxacin have access to culture 
results (or the lack thereof) in the patients they are treating even when another physician ordered the 
culture (or neglected to do so). All nursing home physicians agreed to allow us to retrospectively 
register the indication, diagnosis and culture results of the patients receiving ciprofloxacin under 
their care. Doing this prospectively would raise the issues of informed consent to both physicians 
and patients in whom initiation of ciprofloxacin occurred outside the nursing home, e.g. in the ED 
or at the local hospital. The administrative challenge in these cases would be so considerable that 
many of these patients would not be included in the study. This would reduce the study material 
considerably in both studies, introduce bias and thus reduce the external validity of the studies. 
Performing the studies retrospectively allowed for a more complete, less time consuming database 
generation illustrating another advantage of retrospective observational studies; they cost less. 
 
9.5 The non-randomized intervention cluster study  
Paper IV was a prospective non-randomized cluster intervention study. The Cochrane collaboration 
has a specific set of criteria used to assess bias in interventions designed to improve healthcare 
practice 
128,129
. Optimally, prospective studies should be double blinded and randomized to 
minimize bias. Randomizing minimizes selection bias, an essential criteria for RCTs evaluating the 
effect of a new medical treatment. In intervention studies, however, randomizing is possible but 
blinding is difficult and sometimes impossible. This study would have strengthened if it were a 
multi-center study including several ED‘s over the entire country. Having many participating EDs 
would allow us to randomize the ED‘s into intervention vs control with several ED‘s in each arm. It 
would have also given a larger material strengthening the power of the study. Unfortunately, 
economic and time restraints made a larger study infeasible.  
Blinding of the physicians in the intervention ED was not possible in this study. The 
administrations in the participating EDs were aware of the study but individual ED physicians were 
not specifically informed that the therapy suggestion list or the removal of ciprofloxacin from the 
formulary was part of a study. Nonetheless, their not being informed cannot be viewed as blinding. 
To what degree physician suspicions of being part of a study contributed to the observed reduction 
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of ciprofloxacin prescribing is a possible bias contributing to the lower rates of ciprofloxacin 
prescribing in the intervention ED.  
A reasonable criticism of this study is its inability to determine which of the two 
components of the intervention or if the combination of them was responsible for the observed 
results. To determine this we would have to evaluate each component individually. This would 
require more time, in essence one more year, and resources to have the same power as this study. 
This does not seem necessary. Both components required little effort. Delivery of a printout of the 
urinalysis to the physician is already standard practice. One component involved simply stapling a 
preprinted list located right next to the urinalysis apparatus to the urinalysis output. The other 
component involved removing ciprofloxacin from the formulary for a year. The combination of the 
two components in the intervention could easily be incorporated in the standard practice of a 
Norwegian ED. This makes the clinical relevance of a theoretical but time consuming optimization 
of the study to determine which component was most important questionable. We did not 
systematically question the nurses or physicians about whether this was a burden or whether they 
were inconvenienced by the intervention. This should have been done at the conclusion of the study 
and would clearly strengthen the grounds for the assumption that this intervention was acceptable. 
Nurses, physicians and administration were however informally asked after the intervention about 
their views, and the feed-back was positive. 
 
9.6 External validity 
External validity refers to the relevance of a study in a broader context than the setting in which the 
study was performed. A prerequisite for the external validity of any study is the study‘s internal 
validity. Serious bias or a flawed methodology makes a study‘s external validity irrelevant. 
Unfortunately even a well-designed study with little bias does not guarantee the study‘s external 
validity. This is an especially important consideration in studies focused on antibiotic resistance due 
to the substantial geographic variation in resistance problems and antibiotic prescribing practice.  
  Paper I addresses diagnostic practice when prescribing empiric therapy with a specific 
broad-spectrum antibiotic, ciprofloxacin. Nursing home and hospital physicians initiated pre-
therapy diagnostics for only 51.7 % and 51.5 % of the patients who received ciprofloxacin. This is 
unacceptably low but better than the ED physicians where merely 20 % (1/5) of these elderly 
patients had their urine cultured prior to ciprofloxacin treatment. Both Norwegian and international 
guidelines explicitly recommend urine culture for elderly patients with a suspected UTI 
41,130,131
.  
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In this paper we did not publish whether there was a statistically significant difference in 
diagnostic or prescribing practice between the two wards or the physicians‘ workplace. Neither did 
we evaluate the contribution of individual physicians to the results. There are several reasons for 
this. The aim of this observational study was to document the indication for ciprofloxacin 
prescribing and the extent of microbiologic diagnostics prior to prescribing. If the aim was to 
demonstrate a statistically significant difference between the physicians workplace or between 
individual physicians a much larger sample size would be necessary to have the power to 
demonstrate this difference. This may have generated interesting findings as other studies show that 
individual physician prescribing and physician specialty can contribute to non-compliant antibiotic 
prescribing 
64,132,133
.  
The clinically relevant findings in paper I was the very poor rate of microbiologic 
diagnostics regardless of the physician‘s workplace and high levels of non-compliant prescribing of 
ciprofloxacin for RTI on the short-term wards. A culture rate of urine 50-80 % below national and 
international guidelines demonstrates substantial room for improvement not only for NH physicians 
but for hospital and ED physicians as well. The study also demonstrates that hospital physicians are 
responsible for much of the prescribing on short-term wards illustrating the need for interventions 
aimed beyond the NH to improve guideline adherence for NH patients. Finally, the very low rate of 
pre-therapy microbiologic diagnostics initiated by the ED physicians gives reason to consider a 
separate NH physician based off-hours emergency service for NH patients.  
One can also question the external validity of studies done in municipalities in southeastern 
Norway in other geographical areas. Are the results generalizable domestically not to mention 
abroad? Let us begin at home. There are no significant regional differences in antimicrobial 
resistance within Norway. This would make the external validity of studies done in Arendal 
potentially relevant for the rest of the country seen from a resistance perspective. When it comes to 
prescribing behavior and pre-therapy diagnostics one has to assume that behavior of physicians in 
Arendal does not differ significantly from other parts of the country. None of these studies can 
address this assumption and there is evidence of significant differences in prescribing in both the 
NH, the ED and among family physicians in routine practice settings in Norway 
62-64
.  
The next issue to address is whether the findings in these studies are generalizable outside 
Norway. International variation in the culture of prescribing and use of microbiologic diagnostic 
testing are relevant in gauging the external validity of these papers. The greater the difference in 
resistance problems, the greater the concerns about the external validity of these papers will be. 
Similar resistance patterns and similar cultures in Scandinavia can make the external validity of 
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these studies relevant in these countries. The lack of a clinically relevant difference in uropathogens 
between NH patients and the elderly living at home shown in paper III contrast with similar studies 
from countries outside Scandinavia 
134,135
. This may appear to weaken the external validity of our 
study but the opposite is true. The contrasting conclusions illustrates the need for local/national 
evaluation of resistance prevalence (or lack thereof) between the NH patients and the elderly living 
at home when defining empiric therapy recommendations.  
9.7 Potential for reduction of inappropriate ciprofloxacin prescribing  
Reduction of inappropriate ciprofloxacin prescribing is a theme in all four papers in this thesis. 
Paper IV addresses the issue of reducing unnecessary ciprofloxacin prescribing directly and the 
other three papers address this indirectly. One can ask: What‘s the fuss about ciprofloxacin? It‘s 
paradoxical, but one reason for reducing unnecessary ciprofloxacin prescribing is to preserve the 
possibility for prescribing ciprofloxacin when it is necessary. Another and perhaps equally 
important reason is to avoid adverse ecological effects caused by ciprofloxacin. These untoward 
effects such as C difficile infection and development of resistance to other classes of antibiotics 
exemplified by quinolone linked MRSA emergence affect not only the patient being treated, but 
create problems in the institutions where the patients are treated 
136,137
. These concerns are central in 
the practice of rational antibiotic prescribing which emphasizes prescribing an appropriate antibiotic 
with the narrowest spectrum when necessary.  
9.7.1 Potential for improving antibiotic use with improved diagnostics 
Obtaining a culture specimen prior to prescribing enhances the potential to reduce total broad 
spectrum antibiotics like ciprofloxacin. Although culture results cannot blindly be equated with the 
etiology behind a patient‘s presentation, they can provide valuable clinical information. This 
information can be used to shorten therapy duration in selected patients. Knowledge of the bacterial 
etiology enables switching to a narrower spectrum antibiotic when this is possible. In the first paper 
this information was available in only 52 % of the patients. In these patients ciprofloxacin could 
have been replaced with a narrower spectrum antibiotic in 24/50 patients (48 %) of the cases. In 
15/50 patients (33 %), culture yielded either no growth or was contaminated. Rapid clinical 
improvement in these patients may indicate that an infection was not responsible for the patients‘ 
symptoms allowing physicians to discontinue ciprofloxacin. In 48 % of the patients no culture 
results were available. Without culture results, changing from broad spectrum antibiotic therapy or 
discontinuing therapy is more difficult and potentially places a patient at risk for undertreatment.  
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Paper III challenges the assumption that resistance prevalence among uropathogens from 
elderly in NHs is higher than among the elderly living at home. Studies from other countries have 
supported this assumption 
134,135
. For the two most common bacteria E coli and E faecalis, our study 
showed no significantly higher resistance rate for any of the five antibiotics used for UTIs (table II 
in paper III). Although paper III demonstrated a significantly higher resistance rate for ciprofloxacin 
among K pneumoniae and P mirabilis, the clinical relevance of these findings is less important for 
several reasons. Combined, these two bacteria were only responsible for 9.6 % of the bacteria 
isolated while E coli and E faecalis were responsible for 73.5 %. Furthermore, there was no 
significant difference in resistance rates for mecillinam, nitrofurantoin, or trimethoprim for any of 
these bacteria between the two groups.  
9.7.2 Potential for reduction of non-compliant prescribing  
Ciprofloxacin is no more effective than other antibiotics in the treatment of uncomplicated UTI 
117
. 
In paper IV the aim was to see if it was possible to reduce inappropriate ciprofloxacin prescribing in 
the ED. There was a significant reduction in ciprofloxacin prescribing for cystitis but prescribing 
for pyelonephritis showed no such change. This reduction occurred despite a national increase in 
the sale of ciprofloxacin during the same time period strengthening the evidence that the 
intervention was responsible for the observed reduction in ciprofloxacin prescribing 
138
.  
There are concerns that interventions to reduce broad spectrum antibiotic prescribing may 
result in a shift to another inappropriate antibiotic associated with other resistance problems 
139
. In 
paper IV the opposite of this concern occurred. The decrease in ciprofloxacin prescribing seems to 
have been offset by a significant increase in appropriate pivmecillinam prescribing. There was a 
non-significant increase in cephalexin prescribing in the intervention ED for both cystitis and 
pyelonephritis. However cephalexin was responsible for less than three percent of the antibiotics 
prescribed making the insignificant increase clinically unimportant.  
One criticism of this study is its inability to evaluate precisely how much of the 
ciprofloxacin prescribing was actually indicated and therefore appropriate. The potential that 
reduced appropriate ciprofloxacin prescribing resulted in increased rates of therapy failure though 
possible, seems unlikely. The decrease in ciprofloxacin prescribing occurred concomitantly with a 
rise in pivmecillinam prescribing. Acute uncomplicated UTI (U71) is the second most common 
diagnosis made in the ED setting in Norway 
99
. As in other countries, E coli is the bacteria isolated 
in 75-90 % of the cases of uncomplicated UTI 
140-143
. In Norway, the resistance rates for E coli are 
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lower for mecillinam than ciprofloxacin (5.0 % vs 7.2 %) 
34
 making the theoretic risk of therapy 
failure actually less when physicians prescribe pivmecillinam instead of ciprofloxacin.  
Another situation in which ciprofloxacin may be appropriate is in patients contacting the 
ED due to failure of therapy with another antibiotic. We were unable to know precisely how this 
patient group contributed to the use of ciprofloxacin. Nonetheless, it is unlikely that there are many 
of this type of patient in Norway. Pivmecillinam and trimethoprim are responsible for 
approximately 70 % of the antibiotic prescribing for UTI in the ED (table I in paper IV). Resistance 
rates for E coli in urine samples for pivmecillinam (7.2 %) and trimethoprim (20.4 %) 
34
 remains 
less or close to the 20 % level international guidelines recommend for empiric therapy for 
uncomplicated UVI 
144
. In addition, there is evidence that therapy with trimethoprim is clinically 
effective in about half the cases of uncomplicated UVI even when culture results demonstrate 
trimethoprim resistance illustrating that in vitro testing does not always reflect in vivo effect in UVI 
145-147
. High urine concentrations of antibiotic may result in clinical cure despite in vitro resistance.  
Also, placebo studies indicate that at least 25 % of patients with an uncomplicated UVI will 
experience spontaneous resolution of their symptoms 
148-150
.  The high prescribing rates of these 
effective antibiotics makes the probability of a patient seeking treatment for therapy failure no 
higher than 20.4 % (the resistance rate of E Coli for trimethoprim) and in all probability nearer ten 
percent.  
Even in the case of therapy failure with these antibiotics, ciprofloxacin is not the sole 
alternative. On the contrary, nitrofurantoin is available and a better alternative than ciprofloxacin in 
uncomplicated UTI. In Norway, E coli resistance to nitrofurantoin is substantially lower than 
ciprofloxacin (1.0 % vs 7.2 %) 
34
. E coli resistance to nitrofurantoin is also shown to be low in other 
European and North American studies 
146,151
. In addition, E faecalis, the second most commonly 
cultured uropathogen in paper III is always susceptible to nitrofurantoin in Norway. Ciprofloxacin 
on the other hand, is not recommended for use in infections caused by E faecalis. S saprophyticus is 
often cited as the second most common etiology of uncomplicated UTI 
143,152
 and has generally 
higher susceptibility rates to nitrofurantoin than to ciprofloxacin. These resistance considerations 
make nitrofurantoin a better choice than ciprofloxacin for the treatment of uncomplicated UTI not 
only in Norway but in other countries with ciprofloxacin resistance problems.  
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9.8 Antibiotic stewardship in primary care: How these studies fit in 
Whether they are designed for the use in the hospital, the nursing home, the ED or the outpatient 
clinic antibiotic stewardship programs (ASP) have common features several of which are addressed 
in this thesis (table 4). Regardless of the clinical setting, there are two approaches which roughly 
divide ASP into either a restrictive or persuasive category 
20,66
. The restrictive approach employs 
strategies prior to prescribing and relies on either limiting the antibiotics in the formulary or 
requiring some form of approval before specified antibiotics can be dispensed. In contrast, the 
persuasive approach employs a diverse range of strategies after antibiotics have been prescribed. 
One group of persuasive strategies is based on education and includes guideline development, 
guideline implementation, academic detailing, and auditing prescribing practice. Another group of 
persuasive strategies aims at modifying therapy based on optimal pharmacologic and microbiologic 
considerations. It is not possible to clearly identify which approach, strategy or combination is 
superior, either in general or in the nursing home 
153,154
. The heterogeneous combination of 
strategies in different ASPs makes it difficult to compare which ASP is most effective in achieving 
its goals. In addition, the goals of ASP are also heterogeneous and include reduction of total 
antibiotic prescribing, broad spectrum antibiotic prescribing, guideline adherence, expenditure 
reduction or reducing antibiotic resistance. This heterogeneity in mind, many different interventions 
reach their goals in the short term but long term improvement is more challenging 
83,86,155,156
. 
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9.8.1 The Norwegian guidelines: Adherence and revision suggestions  
A guideline without implementation is like a symphony orchestra without an audience. They 
may be of high quality and they are certainly expensive to develop, but if they have no effect 
then it‘s a waste of resources. Implementation is necessary if the resources invested in guideline 
development are to yield results. There are numerous stumbling blocks hindering physician 
adherence to guidelines. Physicians need to know that the guidelines exist, they must have 
confidence that the guidelines are reliable, and they must be willing to follow them 
172
. Effective 
implementation circumvents these stumbling blocks. 
Systematically examining physician prescribing behavior is a way to evaluate adherence 
to antibiotic guidelines. Papers I and II did this in the nursing home setting, the latter 
demonstrating high rates of compliance (77-79 %) for UTI, RTI and SSTI in comparison to 
studies abroad 
173-175
. These compliance rates are similar to findings from a Norwegian NH study 
from 1998 
90
. The results of our study seen in the light of this previous study may indicate a 
tradition of compliance to antibiotic guidelines in Norway. However, a different Norwegian 
study demonstrated significant variation in antibiotic prescribing between 133 NHs. This study 
did not examine the indication for antibiotic prescribing making evaluation of guideline 
compliance impossible 
62
. Paper IV demonstrated similarly high guideline adherence for cystitis 
(83-88 %) in both EDs both pre and post intervention. For pyelonephritis guideline adherence in 
the intervention ED was 56-59 % while it was 79-85 % in the control ED. The design of this 
paper did not allow us to explain the baseline differences between these two EDs.  
The high level of compliance demonstrated in these papers may imply that guidelines 
are successfully implemented. The first national guidelines for antibiotic prescribing in primary 
care (NGAPC) in Norway were published in 2000 and distributed to all medical students and 
family practice physicians 
102
. Since then, the NGAPCs have been revised in 2008 and in 2013. 
They are available in both book form and electronically 
41,176
. In addition the NGAPCs have 
been harmonized with two of the most frequently used reference resources in Norwegian primary 
care, the Norwegian electronic physician handbook and the Norwegian emergency department 
handbook 
177,178
. As discussed previously, drawing conclusions about the entire country from 
these studies is not possible. Regardless of the uncertainty the NGAPC‘s implementation has in 
explaining the high levels of compliance, implementation is not a static process. Other studies 
clearly demonstrate the ephemeral effects of interventions when they are not part of a continuous 
process 
83,86
. 
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Updating the NGAPC is a continuous process and is part of the Norwegian 
government‘s strategy for prevention of antibiotic resistance 179. Papers II and III address issues 
which can be considered in future versions of the NGAPC. Paper II broaches the issue of empiric 
therapy for infections with an unclear etiology. It is possible that physicians‘ uncertainty 
explains why they prescribe ciprofloxacin in this situation. Specific antibiotic recommendations 
for treating infections of unclear etiology may reduce broad spectrum prescribing. These 
recommendations must be consensus based as there is little evidence documenting the optimal 
antibiotic for this condition in the NH population.  
Paper III challenges the findings in other studies showing that NH patients have 
infections due to microbes with higher rates of antibiotic resistance. Our findings do not give 
grounds to alter the recommendations for UVI therapy in Norwegian NHs in this respect. These 
divergent findings support the often cited need to consider local resistance problems when 
tailoring guidelines. Paper III did however demonstrate significant differences in bacterial 
etiology and resistance prevalence between uropathogens isolated from men and women. It also 
launched a model calculating the risk of empiric therapy failure based on these differences. 
Studies from the intensive care units have calculated the likelihood of inadequate treatment using 
the same principles as in Paper III, demonstrating the need to adapt unit specific 
recommendations to local resistance prevalence 
162,163
. Paper III may indicate different risks of 
empiric antibiotic failure for UTI in men vs women suggesting the need for separate 
recommendations.  
 
9.8.2 Use of restrictions 
Paper IV demonstrates that a combination of formulary restrictions and the use of a clinical 
decision support system (CDSS) based on a therapy suggestion list significantly reduced 
ciprofloxacin prescribing for cystitis. The relative reduction of 46 % though significant was due 
to a seeming less impressive absolute reduction of 2.9 % (from 6.3 % to 3.4 %). However, this 
reduction occurred despite a simultaneous national increase in ciprofloxacin prescribing. This is 
reflected by increased ciprofloxacin prescribing observed in the control ED. A clear advantage of 
this combination intervention was its ease of implementation and minimal use of resources. 
Costs and the time required to establish and maintain an ASP are often cited as their biggest 
obstacles 
65,180
. 
Restriction based interventions may be unpopular among physicians indicated by 
concerns about infringement on prescribing autonomy and ethically inappropriate 
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undertreatment. It is undeniable that restrictions are an infringement on prescribing autonomy, 
but physicians may exaggerate the degree of that infringement 
181
. The potential for unethical 
undertreatment has clear relevance when treating critically ill inpatients and when cost 
containment is a primary impetus for the ASP 
182,183
. These are important concerns but do not 
seem to be relevant in our study. Though not specifically stated, the aim of the study in paper IV 
was not to reduce potentially appropriate antibiotic prescribing for pyelonephritis. The observed 
reduction of only 0.9 % was insignificant. Furthermore, the overwhelming majority of patients 
had cystitis, an uncomfortable but non-serious infection. There were three other antibiotics 
available all equally effective as ciprofloxacin 
117
. In a broader perspective than the individual 
patient, there are obvious ethical issues raised by the overuse of broad-spectrum antibiotics. 
Every prescribing physician has an ethical responsibility to avoid or at least delay resistance 
problems. This is accomplished through rational antibiotic prescribing.  
 
9.8. 3 Use of clinical decision support systems (CDSS) 
The therapy suggestion list accompanying urine dipstick results in paper IV is an example of a 
CDSS. The aim of CDSS is to improve prescribing by automatically providing physicians with 
evidence based suggestions to optimize therapy choice. CDSS can be employed in many clinical 
situations and are not limited to antibiotic prescribing. The format of CDSS can be either paper 
or data based. In general CDSS seem to improve adherence to guidelines
166
. More specifically,  
recent study dealing with RTI in the ED demonstrated that CDSS was effective in improving 
antibiotic prescribing and that a paper based CDSS was equally effective as a data based 
CDSS
120
.  
One criticism of the CDSS portion of our intervention is that symptoms alone are 
sufficient to diagnose uncomplicated cystitis. This would circumvent the need for dipstick 
testing. In the intervention ED there is a tradition but no clear policy that patients with symptoms 
suggestive of an UTI deliver urine for dipstick testing prior to consultation with a physician. 
Nonetheless, we cannot be certain that all the patients were diagnosed with dip-stick testing. The 
physicians evaluating these patients would not have been exposed to the paper based CDSS. This 
could indicate that the other component of the intervention (removing ciprofloxacin from the 
formulary) had a greater role in reducing ciprofloxacin prescribing.  
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9.8.4 Post-prescription modification  
There are several strategies in ASPs which use post prescription modification. De-escalation is 
one form of post-prescription modification which entails switching empiric broad-spectrum 
therapy to narrower spectrum therapy once culture results allow for this. Studies from both 
abroad and from Norway show reduced antibiotic prescribing while reducing costs 
65,171
. The 
issue of post-prescription modification without securing a culture specimen prior to empiric 
therapy was an important theme in Paper I and has been discussed previously in this thesis. Other 
forms of post-prescription modification aim to optimize antibiotic dose, duration, and form of 
administration. In paper I the average daily dose of ciprofloxacin was 887 mg on the short-term 
wards and 882 on the long-term wards. The national guidelines recommend a daily dose of 500 
mg for cystitis and 1000 mg for pyelonephritis. This indicates that pyelonephritis dosing was 
more common than cystitis dosing. It is unlikely that pyelonephritis is more common than 
cystitis suggesting an inappropriately high ciprofloxacin dose in cystitis treatment. An added 
concern is the increased risk of adverse drug reactions in the elderly due to unnecessarily high 
antibiotic dosage. Unfortunately a limit of Paper I was its inability to precisely determine how 
many UTIs were due to cystitis and how many were due to pyelonephritis.  
Another example of post-prescribing modification is shortening the length of antibiotic 
prescribing. The importance of keeping the course of treatment as short as necessary is twofold. 
First, reducing total amount of antibiotics prescribed will contribute less to resistance 
development. The second reason is giving a patient adequate, not excessive treatment. This is 
especially important in elderly patients due to an increased risk of adverse drug reactions. 
Optimal length of treatment for uncomplicated UTI is well documented 
117,144,184
. For other 
infections including both community and nosocomial RTI and UTI in the elderly the optimal 
duration of therapy is more controversial and based on consensus 
185-189
. Results on therapy 
duration were not reported in Paper II due to the uncertainty of therapy duration on the short-
term wards. Initiation of antibiotic therapy on these wards occurred in the hospital in 41 % of 
these patients. The discharge summary rarely specified the date the patient began treatment 
making reliable calculation of therapy duration impossible. A final example of post therapy 
modification is switching from intravenous to oral administration. There was only one patient 
treated with intravenous cefuroxime in study II. At the time of the study intravenous therapy was 
not a routine function in the NH in Arendal. This has since changed. Intravenous therapy of NH 
patients to avoid hospital admission is increasing in Norway, making this form of post-
prescription modification relevant. 
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9.8.5 Is there a need for Antibiotic Stewardship in Norway? 
"To gild refined gold, to paint the lily ... is wasteful and ridiculous excess. (William Shakespeare) 
Or 
“There is always room for improvement”(axiom) 
Seen in a global perspective, Norway along with other Scandinavian countries has relatively 
modest bacterial resistance problems. There is also low total use of antibiotics and low use of 
broad spectrum antibiotics 
22
. ASPs are both time consuming and require economic resources. 
The Norwegian healthcare system, like healthcare systems the world over are forced to prioritize 
resources making it reasonable to question the need for ASPs. 
  The need for ASPs is obvious, both from an economic standpoint but more importantly 
from an ethical standpoint. The threat posed by antibiotic resistance has been compared to the 
threat of global warming 
18
. Both threats are due to excesses in human behavior. Remedies to 
both threats require fundamental changes in human behavior globally. With the lack of new 
antibiotic development coupled with relentless resistance development we need to administer the 
existing antibiotics as if they were a non-renewable resource 
17
. Despite modest resistance 
problems, Norway needs to continue doing everything possible to hinder a further escalation of 
bacterial resistance and thereby prolong the life of existing antibiotics.  
  It is difficult to find reasons not to prioritize ASPs in Norway or elsewhere. Antibiotic 
stewardship advocates appropriate treatment for patients who need it and avoidance of 
unnecessary treatment for patients who do not. It advocates conservation of valuable resources. 
Antibiotic stewardship can be effective in reversing resistance problems both at the individual 
patient level, the institutional level and the national level. It is simply good medical practice.  
   
10 Conclusion 
The areas of improvement identified in this thesis include pre therapy microbiologic diagnostics, 
the need to consider restrictions on prescribing broad spectrum antibiotics and the need for 
specific guidelines for the elderly based on gender for the treatment of UTI. There was relatively 
high compliance with the national guidelines by nursing home physicians. This suggests that 
resources necessary for interventions to improve antibiotic prescribing be used in other settings.  
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11 Further research 
Nitrofurantoin underuse. It is paradoxical that an effective, inexpensive antibiotic which has low 
rates of resistance isn‘t used more frequently. The results of the studies in this thesis seen in the 
light of national prescribing trends indicate that this is a national phenomenon. A literature study 
to systematically evaluate the extent of harmful side effects is warranted. A qualitative study to 
elucidate physicians‘ attitudes towards nitrofurantoin is necessary to understand possible 
explanations for this prescribing practice. 
Better national surveillance of compliance with guideline recommendations. Norway has a 
national prescription registry documenting all prescriptions delivered to pharmacies. Presently 
there is no system for assigning a diagnosis to the prescription. Having the diagnosis consistently 
registered with the antibiotic prescription would provide invaluable information about 
prescribing trends. In turn, this information could fuel further research on improving antibiotic 
prescribing. 
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13 Appendix 1: Errata  
 
1. Side 5.  Borchgrevinck er feil .  Borchgrevink er riktig  
2. Side 16. contributes er feil .  contribute er riktig  
3. Side 20.  
a. Feil: Along with the other Scandinavian countries antibiotic resistance 
problems have been moderate in Norway compared to other European 
countries. 
b. Riktig: Along with the other Scandinavian countries, antibiotic resistance 
problems have been moderate in Norway compared to other European 
countries. 
4. Side 20.  Figure 5 tekst er skjev.  Ordet ―Figure‖ henger ut til hø men bør være rett foran 
―5‖ 
5. Side 21.  
a. Feil : Fluoroquinolone prescribing, primarily ciprofloxacin has increased 74 % 
in the last decade from 0.43 DDD/1000 inhabitants in 2002 to 0.75 DDD/1000 
inhabitants in 2012  
b. Riktig : Fluoroquinolone prescribing, primarily ciprofloxacin, has increased 74 
% in the last decade from 0.43 DDD/1000 inhabitants in 2002 to 0.75 
DDD/1000 inhabitants in 2012 
6. Side 21.  
a. Feil: Ciprofloxacin is also excreted in sweat and contributes to resistance 
development in normal skin bacterial flora 44 
b. Riktig: Ciprofloxacin is also excreted in sweat and contributes to resistance 
development in normal skin bacterial flora 44. 
7. Side 27 
a. Feil: In general, it appears that interventions such as academic detailing aimed 
at physician education appear effective 
b. Riktig : In general, interventions such as academic detailing aimed at physician 
education appear effective 
8. Side 30  
a. Feil :  We searched the patients‘ record 
b. Riktig: We searched the patients‘ records 
9. Side 32 
a. Feil: population of approximately 100000 
b. Riktig: population of approximately 100,000 
 
  
